Here’s How You Can Earn $100 In Passive Income By Investing In Gilead Sciences Stock
December 25, 2024
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below.
Gilead Sciences, Inc. (NASDAQ:GILD), a biopharmaceutical company, discovers, develops and commercializes medicines to address unmet medical needs in the United States, Europe and internationally.
It will report its Q4 2024 earnings on Feb. 11, 2025. Wall Street analysts expect the company to post an EPS of $1.55, down from $1.72 in the year-ago period. According to data from Benzinga Pro, quarterly revenue is expected to be $7.14 billion, slightly up from $7.12 billion in the year-ago period.
Don’t Miss:
-
Unlock the hidden potential of commercial real estate — This platform allows individuals to invest in commercial real estate offering a 12% target yield with a bonus 1% return boost today!
-
This Jeff Bezos-backed startup will allow you to become a landlord in just 10 minutes, with minimum investments as low as $100 for properties like the Byer House from Stranger Things.
The 52-week range of Gilead Sciences stock price was $62.07 to $98.90.
Gilead Sciences’ dividend yield is 3.38%. During the last 12 months, it paid $3.08 per share in dividends.
On Nov. 6, the company announced its Q3 2024 earnings, posting an adjusted EPS of $2.02, compared to the consensus estimate of $1.55 and revenues of $7.54 billion, compared to the consensus of $7 billion, as reported by Benzinga.
“Gilead’s third-quarter results are the strongest of the year to date, with 7% year-over-year revenue growth, including 13% year-over-year growth for Biktarvy. Based on this very strong topline growth and disciplined operating expense management, we are increasing our full-year revenue, operating income and earnings per share guidance,” said Daniel O’Day, Gilead’s Chairman and Chief Executive Officer.
See Also: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — you can become an investor for $0.80 per share today.
The company now expects full-year product sales in the range of $27.8-$28.1 billion, compared to the prior guidance of $27.1-$27.5 billion.
Check out this article by Benzinga, which analyzes Gilead Sciences’s short interest.
If you want to make $100 per month – $1,200 annually – from Gilead Sciences dividends, your investment value needs to be approximately $35,503, which is around 390 shares at $91.09 each.
Understanding dividend yield calculations: When estimating, you need two key variables – the desired annual income ($1,200) and the dividend yield (3.38% in this case). So, $1,200 / 0.0338 = $35,503 to generate an income of $100 per month.
You can calculate the dividend yield by dividing the annual dividend payments by the stock’s current price.
Trending: Commercial real estate has historically outperformed the stock market, and this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!
The dividend yield can change over time due to fluctuating stock prices and dividend payments on a rolling basis.
For instance, assume a stock that pays $2 as an annual dividend is priced at $50. Its dividend yield would be $2/$50 = 4%. If the stock price rises to $60, the dividend yield drops to 3.33% ($2/$60). A drop in stock price to $40 will have an inverse effect and increase the dividend yield to 5% ($2/$40).
In summary, income-focused investors may find Gilead Sciences stock an attractive option for making a steady income of $100 per month by owning 390 shares of stock. There may be more upside as investors benefit from the company’s consistent dividend hikes. Gilead Sciences has raised its dividend consecutively for the last nine years.
Wondering if your investments can get you to a $5,000,000 nest egg? Speak to a financial advisor today. SmartAsset’s free tool matches you up with up to three vetted financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
A 9% Return In Just 3 Months
EquityMultiple’s ‘Alpine Note — Basecamp Series’ is turning heads and opening wallets. This short-term note investment offers investors a 9% rate of return (APY) with just a 3 month term and $5K minimum. The Basecamp rate is at a significant spread to t-bills. This healthy rate of return won’t last long. With the Fed poised to cut interest rates in the near future, now could be the time to lock in a favorable rate of return with a flexible, relatively liquid investment option.
What’s more, Alpine Note — Basecamp can be rolled into another Alpine Note for compounding returns, or into another of EquityMultiple’s rigorously vetted real estate investments, which also carry a minimum investment of just $5K. Basecamp is exclusively open to new investors on the EquityMultiple platform.
Looking for fractional real estate investment opportunities? The Benzinga Real Estate Screener features the latest offerings.
This article Here’s How You Can Earn $100 In Passive Income By Investing In Gilead Sciences Stock originally appeared on Benzinga.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Search
RECENT PRESS RELEASES
Related Post
